liver disease mash - Search News

News

Novo Nordisk, Liver

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

· 5h · on MSN

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

· 9h · on MSN

Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

49m

A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

MPR53m

Wegovy Approved for Noncirrhotic MASH With Moderate, Advanced Liver Fibrosis

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

Medscape6h

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The American Journal of Managed Care1h

FDA Approves Semaglutide for MASH With Fibrosis

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

The New England Journal of Medicine4d

Metabolic Dysfunction–Associated Steatotic Liver Disease

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results